Oral JAK1/2 inhibitor, LN3103801 treatment alleviated the pathology changes of JAK2 overexpression in diabetic mice.254 The overexpression of E3 ubiquitin ligase casitas B-lineage lymphoma (Cbl) degraded JAK2, and inactivated the successive STAT4 and the targeted Runx3 transcription, resulting in the inhibition of endothelial dysfunction by increasing NO production.255 STAT6 was increased in TECs and STAT6 deficiency attenuated UUO-induced renal fibrosis. Here, JAK2 is linked to endothelial dysfunction.